BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24572100)

  • 21. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessments of antibody biodistribution.
    Glassman PM; Abuqayyas L; Balthasar JP
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S29-38. PubMed ID: 25707961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).
    Nunes JP; Morais M; Vassileva V; Robinson E; Rajkumar VS; Smith ME; Pedley RB; Caddick S; Baker JR; Chudasama V
    Chem Commun (Camb); 2015 Jul; 51(53):10624-7. PubMed ID: 26051118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.
    Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M
    J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues.
    Boswell CA; Mundo EE; Ulufatu S; Bumbaca D; Cahaya HS; Majidy N; Van Hoy M; Schweiger MG; Fielder PJ; Prabhu S; Khawli LA
    Mol Pharm; 2014 May; 11(5):1591-8. PubMed ID: 24702191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
    Vu TT; Kim K; Manna M; Thomas J; Remaily BC; Montgomery EJ; Costa T; Granchie L; Xie Z; Guo Y; Chen M; Castillo AMM; Kulp SK; Mo X; Nimmagadda S; Gregorevic P; Owen DH; Ganesan LP; Mace TA; Coss CC; Phelps MA
    Pharmacol Res; 2024 Jan; 199():107048. PubMed ID: 38145833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA-DQ8 Supports Development of Insulitis Mediated by Insulin-Reactive Human TCR-Transgenic T Cells in Nonobese Diabetic Mice.
    Racine JJ; Misherghi A; Dwyer JR; Maser R; Forte E; Bedard O; Sattler S; Pugliese A; Landry L; Elso C; Nakayama M; Mannering S; Rosenthal N; Serreze DV
    J Immunol; 2023 Dec; 211(12):1792-1805. PubMed ID: 37877672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.
    Bauer-Smith H; Sudol ASL; Beers SA; Crispin M
    Biochim Biophys Acta Gen Subj; 2023 Nov; 1867(11):130448. PubMed ID: 37652365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a New Method to Evaluate the Biodistribution of Antibodies Using Non-Radioactive Metal Labeling and Inductively Coupled Plasma Mass Spectrometry.
    Nagayasu M; Takano Y; Ozeki K
    Pharm Res; 2023 Jul; 40(7):1807-1819. PubMed ID: 37266817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the Targeting of a
    van Dijk B; Hooning van Duyvenbode JFF; de Vor L; Nurmohamed FRHA; Lam MGEH; Poot AJ; Ramakers RM; Koustoulidou S; Beekman FJ; van Strijp J; Rooijakkers SHM; Dadachova E; Vogely HC; Weinans H; van der Wal BCH
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies.
    Salimi-Moosavi H; Soto M
    AAPS J; 2022 Nov; 24(6):116. PubMed ID: 36376552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies.
    Rafidi H; Rajan S; Urban K; Shatz-Binder W; Hui K; Ferl GZ; Kamath AV; Boswell CA
    MAbs; 2022; 14(1):2085535. PubMed ID: 35867780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation.
    Haraya K; Tsutsui H; Komori Y; Tachibana T
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
    Abu-Dief AM; Alsehli M; Awaad A
    Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human monoclonal antibodies against
    de Vor L; van Dijk B; van Kessel K; Kavanaugh JS; de Haas C; Aerts PC; Viveen MC; Boel EC; Fluit AC; Kwiecinski JM; Krijger GC; Ramakers RM; Beekman FJ; Dadachova E; Lam MG; Vogely HC; van der Wal BC; van Strijp JA; Horswill AR; Weinans H; Rooijakkers SH
    Elife; 2022 Jan; 11():. PubMed ID: 34989676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.
    Al Ojaimi Y; Blin T; Lamamy J; Gracia M; Pitiot A; Denevault-Sabourin C; Joubert N; Pouget JP; Gouilleux-Gruart V; Heuzé-Vourc'h N; Lanznaster D; Poty S; Sécher T
    Pharmacol Ther; 2022 May; 233():108022. PubMed ID: 34687769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.